A key lupus outcome measure is the assessment of damage, which is considered as a separate domain to disease activity and health related quality of life and has been shown to independently predict ...

Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids.2 As ...

Systemic lupus erythematosus (SLE) is a clinically and immunologically heterogeneous autoimmune disease that can be challenging to diagnose, especially in its early stages. Although developed in the ...

Systemic lupus erythematosus (SLE) is a systemic disease with cardiac manifestations, of which pericarditis is the most common (a lifetime risk of 25%) 1 and myocarditis a less common (5–10%)2 but ...

Malignancy risk in systemic lupus erythematosus (SLE) is about 15% higher than the general age-and-sex-matched population. Hematologic cancers, especially B-cell lymphomas, are about three-fold ...

Immune dysregulation in systemic lupus erythematosus (SLE) results in the autoimmune manifestations of SLE, but also leads to an impaired immune response to pathogens and vulnerability to infections ...

Despite advancements in lupus management over the past two decades, infection remains a significant cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). 1 2 Various ...

Background The current recommendations for the treatment of LN consider as the standard of care (SoC) the use of MMF or CYC. Considering the expanding evidence for using calcineurin inhibitors (CNI) ...

Background Kidney involvement is common in lupus. Lupus and kidney diseases incur poor outcomes in people from racial/ethnic minority groups. Previous studies have utilized the national registry of ...

402 Study design and rationale for the efficacy and safety assessment of daxdilimab, a selective plasmacytoid dendritic cell depleter, in a phase 2 trial of patients with moderate-to-severe primary ...

Objective Whereas genetic susceptibility for Systemic Lupus Erythematosus (SLE) has been well explored, the triggers for clinical disease flares remain elusive. To investigate relationships between ...

Background Despite optimal treatment, lupus nephritis (LN) remains associated with irreversible kidney damage. 1 A better understanding of the mechanisms underlying LN pathogenesis is needed to ...